Scopus BioPharma Inc. (NASDAQ: SCPS) has reported approval of an investigational new drug application by the U.S. FDA for CpG-STAT3siRNA, the immune-oncology RNA therapy to treat multiple cancers. Phase 1 clinical trial for B-cell non-Hodgkin lymphoma will be initiated at City of Hope.
Scopus focuses on developing transformational therapeutics that is based on scientific and medical discoveries. City of Hope is an independent research and treatment center for diabetes, cancer and other life threatening diseases near Los Angeles, California.
CpG-STAT3siRNA has both RNA therapy and immunotherapy by linking siRNA to oligonucleotide TLR9 agonist, to create the potential for targeted gene silencing with simultaneous TLR stimulation and immune activation in the tumor microenvironment.